Navigation Links
EMcision Announces 510(k) Clearance of the Habib EndoHPB, its Novel Bipolar RF Device for the Palliation of Biliary and Pancreatic Tumours
Date:7/14/2009

EMcision Ltd. today announced clearance for marketing by the United States Food and Drug Administration (K083292) of its Habib™ EndoHPB device for the palliation of biliary and pancreatic tumours.

London (PRWEB) July 14, 2009 -- EMcision Ltd. today announced clearance for marketing by the United States Food and Drug Administration (K083292) of its Habib™ EndoHPB device for the palliation of biliary and pancreatic tumours.

The Habib™ EndoHPB is an endoscopic bipolar radiofrequency (RF) catheter that allows for:

1) Destruction of biliary tumours prior to stent insertion: Currently, endoscopic plastic stents become clogged by sludge or by tumour pressure narrowing the stent lumen, necessitating regular changing of the stent. Use of the Habib™ EndoHPB prior to stent insertion improves the stent patency by delaying tumour growth.

2) Clearance of obstructed metal stents: Self-expanding mesh metal stents (SEMS), which have longer patency and lower occlusion rates, are still subject to obstructive tumour in-growth. Since SEMS cannot be removed, the Habib™ EndoHPB can be used to ablate the occluding tissue.

"The EndoHPB significantly improves on the procedure for patients suffering from malignant biliary obstruction," stated EMcision's CEO, the internationally renowned surgeon, Professor Nagy Habib. "I am particularly excited about the EndoHPB's application in clearing obstructed metal stents, which represents a real innovation. As a surgeon, I prefer simple and elegant systems and I believe we have achieved that with the EndoHPB. Interventional radiologists and endoscopists who use it tell us they like its convenience and efficacy, and administrators look kindly on the fact that no capital expenditure is required."

The Habib™ EndoHPB is inserted by the interventional radiologist in cases of hilar cholangiocarcinoma or by the endoscopist for tumours in the lower bile duct and head of pancreas. It is a sterile, single-use device compatible with the most commonly used RF generators. The fifth in EMcision's line of medical devices, the EndoHPB is CE marked and has earned considerable positive feedback from its use in clinical settings throughout Europe.

The Company's first product, the Habib™ 4X™, captured close to 30% share of the US hepatic resection market following its introduction under exclusive license to AngioDynamics (NASDAQ: ANGIO). "We expect similar success with the EndoHPB," stated Prof. Habib.

EMcision seeks U.S. distributors to help with this product rollout.

About EMcision:
Founded in 2001 to develop and commercialize clinically relevant and cost-effective medical devices which enhance the quality of patient care, EMcision Limited has introduced a series of innovative proprietary medical devices based on proven RF technology. EMcision's founder, Chairman and CEO Prof. Nagy Habib is also Chair of Surgery and Head of Liver and Pancreatic Surgery at Imperial College London and Hammersmith Hospital. The Company is backed by a group of investors, including the Imperial College University Challenge Seed Fund.

###

Read the full story at http://www.prweb.com/releases/2009/07/prweb2634994.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Xanodyne Announces New Executive Team Members
2. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2009 Earnings Release and Conference Call
3. Jesup & Lamont Announces Presenting LifeTech Companies and Former FDA Commissioner at Annual Growth Stock & National Sales Conference
4. Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System
5. MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
6. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2009 Financial Results
7. Mirixa Corporation Announces Key New Hires
8. Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia
9. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
10. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
11. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a ... designed, tuned and optimized exclusively for Okuma CNC machining centers at The International ... a collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
Breaking Biology Technology:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
Breaking Biology News(10 mins):